Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - Taylor & Francis
For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …
被引用次数：98 相关文章

[引用][C] Apixaban, an oral direct Factor Xa inhibitor: A waiting the verdict

J CARREIRO - Expert Opin Investig Drugs, 2008 - cir.nii.ac.jp

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict.

J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - europepmc.org
For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

J Carreiro, J Ansell - Expert opinion on investigational …, 2008 - pubmed.ncbi.nlm.nih.gov
For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

[引用][C] Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict

J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - cir.nii.ac.jp
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす 大学図書館の本をさがす 日本の …